NSC2500 Pharmacology Report: Cancer, Adriamycin, and Treatment

This report examines the pharmacology of cancer, focusing on the use of Adriamycin (doxorubicin) in treatment. The abstract discusses non-hormonal cancers, specifically triple-negative breast cancer, and the disruption of homeostasis involving lipin 1, insulin, and adinopectin. It outlines the pathophysiological symptoms, including visceral metastasis, cellular fibrosis, and brain metastasis. The report details Adriamycin's mechanism of action, targeting DNA through intercalation and inhibiting topoisomerase II. It also covers the pharmacokinetics, including one-electron reduction, and the drug's half-life. The report mentions various routes of administration, such as intravenous, and potential side effects, including nausea and vomiting. The report also suggests nursing practices for managing the disease, such as care plans for triple-negative breast cancers. This report aims to provide a comprehensive overview of cancer pharmacology and the use of Adriamycin in cancer treatment, emphasizing its importance for women's health.